Nachrichten zur ASTRAZENECA PLC DL-,25 Aktie

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.Evinova wird als eigenständiger Health-Tech-Geschäftsbereich innerhalb von…

J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant

J&Js (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on…

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical…

AstraZeneca: Leading bank tells us why the stock is a core holding

Barclays Capital has issued an optimistic assessment of AstraZeneca PLC (LSE:AZN)s shares, recommending an "overweight" position with a target price…

Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with…

AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Dont Rush to Buy the Stock

It might have a hard time finding a home in the market.…

CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage

The CDCs move to increase availability of Beyfortus, a monoclonal antibody from Sanofi and AstraZeneca, comes as RSV cases rise…

Truqap approved in US for HR+ breast cancer

17 November 2023 Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer First-in-class AKT inhibitor has potential to reshape…

Pharma Stock Roundup: FDA Okays AZNs Capivasertib & MRKs Keytruda Expanded Use

FDA approves AstraZenecas (AZN) new breast cancer drug, Truqap, and the expanded use of Mercks (MRK) Keytruda in a gastric…

AstraZenecas (AZN) Capivasertib Gets FDA Nod for Breast Cancer

AstraZenecas (AZN) capivasertib gets approval in combination with Faslodex for HR-positive, HER2-negative metastatic breast cancer.…

Cellectis stock jumps on execution of $140M additional investment with AstraZeneca

…

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that,…

AstraZenecas (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

AstraZenecas (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.…

Astrazeneca: Wichtiges Medikament erreicht Ziel in Lungenkrebsstudie nicht

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem seiner Kassenschlager erlitten. Eine…

Astrazeneca: Wichtiges Medikament erreicht Ziel in Lungenkrebsstudie nicht

CAMBRIDGE (dpa-AFX) - Der Pharmakonzern Astrazeneca hat in Studien mit Lungenkrebs-Patienten einen Rückschlag bei einem…

Kaum Impulse für die AstraZeneca-Aktie (59,2271 €)

Im Wertpapierhandel ist der Anteilsschein von AstraZeneca zur Stunde unauffällig. Die Aktie notiert derzeit bei 63,37 US-Dollar. Der heutige Börsentag…

AstraZeneca: Jahresziele erhöht - Aktienanalyse

Kulmbach (www.aktiencheck.de) - AstraZeneca-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie des…

Week In Review: Eccogen Out-Licenses GLP-1 Agonist To AstraZeneca In $2 Billion Deal

…

AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead

"The incumbent almost always wins," Jim Cramer said this week.…

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.…

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral…

AstraZeneca Plc (AZN) Q3 2023 Earnings Call Transcript

AZN earnings call for the period ending September 30, 2023.…

AstraZeneca PLC 2023 Q3 - Results - Earnings Call Presentation

…

AstraZeneca PLC (AZN) Q3 2023 Earnings Call Transcript

…

Theres a new entry into the weight loss drug boom. Heres the outlook for the stock

AstraZeneca is the latest player to enter the weight loss drug market, which analysts predict could reach $100 billion by…

AstraZeneca CFO: Obesity Market Has a Lot of Potential

AstraZeneca CFO Aradhana Sarin discusses the companys third-quarter results and its plans to develop an obesity pill. The treatment developed…

FTSE 100 helped higher by AstraZeneca and Taylor Wimpey

The FTSE 100 gained on Thursday as macroeconomic concerns took a back seat and investors focused on corporate earnings. Upbeat…

Director Declaration

9 November 2023 15:00 BST Director Declaration AstraZeneca PLC (the Company) today announced that Philip Broadley,senior independent Non-Executive Directorof the Company, has…

AstraZeneca Paying Up To $2 Billion For Experimental Obesity Pill—As Weight Loss Drug Market Grows

The drug is similar to Ozempic, which is commonly used for diabetes and weight loss.…

AstraZeneca could "take some reassurance” from obesity drug bet

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year in the hope that its foray into a semaglutide…

AstraZeneca: "Take some reassurance” from obesity drug bet

AstraZeneca PLC (LSE:AZN) has upgraded its sales forecast for the year, in the hope that its foray into a semaglutide…

AstraZeneca erhöht Ziele und sichert sich Rechte an Abnehmpille

London (Reuters) - Der britische Pharmakonzern AstraZeneca erhöht dank starker Nachfrage nach seinen Krebsmedikamenten die Geschäftsziele für dieses Jahr.

Inmitten…

ROUNDUP: Astrazeneca stemmt sich gegen Umsatzschwund im Covid-Geschäft

CAMBRIDGE (dpa-AFX) - Astrazeneca hat den Umsatzschwund bei Covid-Arzneien auch im dritten Quartal gut verkraftet. Der britisch-schwedische Pharmakonzern profitierte…

KORREKTUR: Astrazeneca stemmt sich gegen Umsatzschwund im Covid-Geschäft

(Korrigiert wird im Text die Währung. Astrazeneca berichtet in US-Dollar rpt US-Dollar.) CAMBRIDGE…

Movers & Shakers: Virgin Galactic shares surge as space firm doubles revenue while Walt Disney stock jumps on spike in streaming customers

Shares in Virgin Galactic, Bill Holdings, Walt Disney Co, AstraZeneca, Topgolf Callaway, Allbirds, Bill Holdings, and Lyft shares were all…

dpa-AFX ProFeed